| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3937 | Ouabain | Natural inhibitor of the Na+/K+-ATPase sodium-potassium ion pump |
|
| DCC3938 | oup-186 | High affinity and human/rat species-selective histamine H3 receptor antagonist |
|
| DCC3939 | Ova257-264 Peptide | Ovalbumin fragment peptide as a class I (Kb)-restricted peptide epitope, triggering T cell activation in immunology studies |
|
| DCC3940 | Ova323-339 Peptide | Ovalbumin fragment peptide for study class II MHC-peptide binding and T-cell activation, binding to I-A(d) MHC class II protein, encompassing an allergenic and antigenic epitope of the ovalbumin protein |
|
| DCC3941 | Ovatodiolide | Narural broad anticancer agent, upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K/AKT/mTOR pathway |
|
| DCC3942 | Ov-potentiator-28 | First-in-class small molecule potentiator of cancer virotherapy, significantly enhancing virus replication-associated luciferase expression specifically in the tumor |
|
| DCC3943 | Ox02983 | Novel anthelmintic agent, immobilising whipworm and reducing the ability of embryonated T. muris eggs to establish infection in the mouse host in vivo |
|
| DCC3944 | Ox03699 | Novel anthelmintic agent |
|
| DCC3945 | Ox1r Antagonist 56 | Brain penetrant, selective and high affinity OX1R antagonist |
|
| DCC3946 | Ox2r-in-f7.3 | Novel selective Ligand for the Orexin 2 Receptor (OX2R) |
|
| DCC3947 | Oxa-06 Dihydrochloride | Potent inhibitor of PANC-1 cell migration and MYPT1 phosphorylation |
|
| DCC3948 | Oxaz-1 | Novel dual inhibitor of the p53 interaction with MDM2 and MDMX |
|
| DCC3949 | Oxeglitazar | PPARalpha/gamma agonist |
|
| DCC3950 | Oxendolone | Novel potent inhibitor of GVIA iPLA2 with little or no inhibition against GIVA cPLA2 (XI(50) = 0.0073 and >0.91, respectively) |
|
| DCC3951 | Oxfbd03 | Novel inhibitor of the bromodomain and extra terminal domain (BET) bromodomain family member BRD4(1) |
|
| DCC3952 | Oxiperomide Featured | Dual dopamine D2 and muscarinic M1 receptor ligand with putative antipsychotic and pro-cognitive potential |
|
| DCC3953 | Oxocarbazate | Novel inhibitor of human cathepsin L |
|
| DCC3954 | Oxs000675 | Novel inducer of differentiation in all six AML cell lines |
|
| DCC3955 | Oxt-328 | Novel sulindac derivative; anti-inflammatory and anti-cancer agent |
|
| DCC3956 | Oxyfedrine Hydrochloride | Vasodilator and β-adrenoreceptor agonist |
|
| DCC3957 | Oxyl Surfen | Antagonist of cell-surface heparan sulfate and heparin-protein interactions, reducing tau hyperphosphorylation and mitigating or delaying neuronal defects in tauopathies, including Alzheimer's disease |
|
| DCC3958 | Oxymetholone | Synthetic hormone with anabolic and androgenic properties |
|
| DCC3959 | Oxymorphindole | δ-Opioid receptor agonist |
|
| DCC3960 | P18in005 Hydrochloride | Novel p18(INK4C) inhibitor |
|
| DCC3961 | P18smi-21 | Novel INK4C inhibitor, specifically blocking the bioactivity of p18 protein |
|
| DCC3962 | P18smi-22 | Novel INK4C inhibitor, specifically blocking the bioactivity of p18 protein |
|
| DCC3963 | P18smi-41 | Novel INK4C inhibitor, specifically blocking the bioactivity of p18 protein |
|
| DCC3964 | P217564 | Second-generation active site-targeted covalent irreversible inhibitor of USP7 |
|
| DCC3965 | P-2281 Featured | Novel potent inhibitor of mTOR activity, significantly suppressing macroscopic and histologic abnormalities associated with chemically-induced murine ulcerative colitis. |
|
| DCC3966 | P2y1-in-16 | Novel P2Y1 Antagonist |
|
